Shares of Syndax Pharmaceuticals (SNDX) have gained 2.2% over the past four weeks to close the last trading session at $9.57, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of$32.33 indicates a potential upside of 237.8%.The mean estimate comprises 12 short-term price targets with a standard deviation of $10.46. While the lowest estimate of$17.00 indicates a 77.6% increase from ...